TABLE 3.

Most frequent AEs observed during the study

AENo. (%) with AE
Canakinumab (n = 25)Control (n = 26)
Headache3 (12.0)5 (19.2)
Influenza-like syndrome/aching0 (0.0)2 (7.7)
Pharyngitis0 (0.0)2 (7.7)